Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Notes Payables (2020 - 2022)

Seres Therapeutics' Notes Payables history spans 4 years, with the latest figure at $456000.0 for Q4 2022.

  • For Q4 2022, Notes Payables changed N/A year-over-year to $456000.0; the TTM value through Dec 2022 reached $456000.0, changed N/A, while the annual FY2022 figure was $456000.0, N/A changed from the prior year.
  • Notes Payables for Q4 2022 was $456000.0 at Seres Therapeutics, down from $9.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $9.3 million in Q3 2021 and bottomed at $454000.0 in Q4 2020.
  • The 3-year median for Notes Payables is $3.3 million (2021), against an average of $4.0 million.